Johnson & Johnson Unit Defeated In Oxybutynin Case; Mylan To Produce Generic Version

Law360, New York (September 28, 2005, 12:00 AM EDT) -- In a stinging defeat for Johnson & Johnson’s Alza Corp., a federal court has ruled that Mylan’s generic version of the overactive bladder treatment Ditropan XL does not infringe on Alza’s patents.

Mylan’s version of the drug did not violate Alza’s patents due to its unique delivery system, the federal district court in the Northern District of West Virginia ruled.

The court declared Alza’s patent invalid, calling it “anticipated and obvious,” according to a press release from Mylan.

Alza initiated the suit against Mylan in May...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.